Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun 5;15(1):326-330.
doi: 10.1515/biol-2020-0035. eCollection 2020.

Progress in research on the role of fibrinogen in lung cancer

Xing Liu  1 , Bin Shi  1
Affiliations
Review

Progress in research on the role of fibrinogen in lung cancer

Xing Liu et al. Open Life Sci. .

Abstract

Lung cancer is one of the most prevalent malignancies worldwide. Local recurrence and distant metastasis remain the major causes of treatment failure. It has been recognized that the process of tumor growth and metastasis involves multiple interactions between tumor and host. Various biomarkers have been used for predicting tumor recurrence, metastasis, and prognosis in patients with lung cancer. However, these biomarkers are still controversial and require further validation. The relationship between malignancy and coagulation system disorders has been explored for more than a century. Fibrinogen is the most abundant plasma coagulation factor synthesized mainly by hepatic cells. Increased plasma fibrinogen levels were observed in various carcinomas such as gastric cancer, colon cancer, and pancreatic cancer. Recent studies have also investigated the role of fibrinogen in patients with lung cancer. This review aimed to address the role of fibrinogen in lung cancer.

Keywords: cancer biomarkers; fibrinogen; lung cancer.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: The authors state no conflict of interest.

References

    1. Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran Jr WJ, Wu YL, et al. Lung cancer: current therapies and new targeted treatments. Lancet. 2017;389:299–311. - PubMed
    2. Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran Jr WJ, Wu YL. et al. Lung cancer: current therapies and new targeted treatments. Lancet. 2017;389:299–311. - PubMed
    1. Cho HI, Lung J. Cancer biomarkers. Adv Clin Chem. 2015;72:107–70. - PubMed
    2. Cho HI, Lung J. Cancer biomarkers. Adv Clin Chem. 2015;72:107–70. - PubMed
    1. Hassanein M, Callison JC, Callaway-Lane C, Aldrich MC, Grogan EL, Massion PP. The state of molecular biomarkers for the early detection of lung cancer. Cancer Prev Res. 2012;5:992–1006. - PMC - PubMed
    2. Hassanein M, Callison JC, Callaway-Lane C, Aldrich MC, Grogan EL, Massion PP. The state of molecular biomarkers for the early detection of lung cancer. Cancer Prev Res. 2012;5:992–1006. - PMC - PubMed
    1. Jones JM, McGonigle NC, McAnespie M, Cran GW, Graham AN. Plasma fibrinogen and serum C-reactive protein are associated with non-small cell lung cancer. Lung Cancer. 2006;53:97–101. - PubMed
    2. Jones JM, McGonigle NC, McAnespie M, Cran GW, Graham AN. Plasma fibrinogen and serum C-reactive protein are associated with non-small cell lung cancer. Lung Cancer. 2006;53:97–101. - PubMed
    1. Zhao J, Zhao M, Jin B, Yu P, Hu X, Teng Y, et al. Tumor response and survival in patients with advanced non-small-cell lung cancer: the predictive value of chemotherapy-induced changes in fibrinogen. BMC Cancer. 2012;12:330. - PMC - PubMed
    2. Zhao J, Zhao M, Jin B, Yu P, Hu X, Teng Y. et al. Tumor response and survival in patients with advanced non-small-cell lung cancer: the predictive value of chemotherapy-induced changes in fibrinogen. BMC Cancer. 2012;12:330. - PMC - PubMed

LinkOut - more resources